rabbit anti gfap  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Name:
    Anti GFAP Antibody
    Description:

    Catalog Number:
    PA1239
    Price:
    99.0
    Category:
    Primary Antibodies
    Reactivity:
    Human Mouse Rat
    Applications:
    IF, IHC, WB
    Immunogen:
    A synthetic peptide corresponding to a sequence at the C-terminus of human GFAP(417-432aa DGEVIKESKQEHKDVM), identical to the related rat sequence, and different from the related mouse sequence by two amino acids.
    Host:
    Rabbit
    Buy from Supplier


    Structured Review

    Boster Bio rabbit anti gfap
    Anti GFAP Antibody

    https://www.bioz.com/result/rabbit anti gfap/product/Boster Bio
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti gfap - by Bioz Stars, 2021-09
    95/100 stars

    Images

    1) Product Images from "Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1"

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1

    Journal: bioRxiv

    doi: 10.1101/2020.05.20.106153

    EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.
    Figure Legend Snippet: EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.

    Techniques Used: Expressing, Immunohistochemistry, Staining, Mouse Assay, Western Blot

    A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.
    Figure Legend Snippet: A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.

    Techniques Used: Cell Culture, Staining, Immunohistochemistry, Expressing, Western Blot

    2) Product Images from "Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1"

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1

    Journal: bioRxiv

    doi: 10.1101/2020.05.20.106153

    EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.
    Figure Legend Snippet: EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.

    Techniques Used: Expressing, Immunohistochemistry, Staining, Mouse Assay, Western Blot

    A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.
    Figure Legend Snippet: A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.

    Techniques Used: Cell Culture, Staining, Immunohistochemistry, Expressing, Western Blot

    3) Product Images from "Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1"

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1

    Journal: bioRxiv

    doi: 10.1101/2020.05.20.106153

    EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.
    Figure Legend Snippet: EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.

    Techniques Used: Expressing, Immunohistochemistry, Staining, Mouse Assay, Western Blot

    A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.
    Figure Legend Snippet: A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.

    Techniques Used: Cell Culture, Staining, Immunohistochemistry, Expressing, Western Blot

    4) Product Images from "Graphene oxide suppresses the growth and malignancy of glioblastoma stem cell-like spheroids via epigenetic mechanisms"

    Article Title: Graphene oxide suppresses the growth and malignancy of glioblastoma stem cell-like spheroids via epigenetic mechanisms

    Journal: Journal of Translational Medicine

    doi: 10.1186/s12967-020-02359-z

    The molecular mechanism underlying GO-inhibited transcription in GSCs. GO downregulates the epigenetic methyl transferase EZH2 and enhances the expression of the differentiation related genes TUJ1 and GFAP. Data represent the mean ± SEM of at least three independent experiments
    Figure Legend Snippet: The molecular mechanism underlying GO-inhibited transcription in GSCs. GO downregulates the epigenetic methyl transferase EZH2 and enhances the expression of the differentiation related genes TUJ1 and GFAP. Data represent the mean ± SEM of at least three independent experiments

    Techniques Used: Expressing

    Graphene oxide inhibits the cell viability and promotes the differentiation of U251 GSCs. a U251 cells were cultured in a serum-free environment. Sphere morphology was photographed using light microscopy. Scale bar = 100 μm. b The expression of SOX2, CD133 and OCT4 in glioblastoma stem-like cells was increased during different periods. c Morphological appearance of U251 GSCs with or without treatment with GO for 2 days. The GSC spheres treated with GO showed adherent growth. Scale bar = 100 μm. d An MTT assay showed the cell viability of U251 GSCs with or without treatment with different dosages of GO for 2, 4, and 6 days. e Quantification of the mRNA levels of the stem cell markers SOX2 and differentiation markers (GFAP and TUJ1) in U251 GSCs with or without treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p
    Figure Legend Snippet: Graphene oxide inhibits the cell viability and promotes the differentiation of U251 GSCs. a U251 cells were cultured in a serum-free environment. Sphere morphology was photographed using light microscopy. Scale bar = 100 μm. b The expression of SOX2, CD133 and OCT4 in glioblastoma stem-like cells was increased during different periods. c Morphological appearance of U251 GSCs with or without treatment with GO for 2 days. The GSC spheres treated with GO showed adherent growth. Scale bar = 100 μm. d An MTT assay showed the cell viability of U251 GSCs with or without treatment with different dosages of GO for 2, 4, and 6 days. e Quantification of the mRNA levels of the stem cell markers SOX2 and differentiation markers (GFAP and TUJ1) in U251 GSCs with or without treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p

    Techniques Used: Cell Culture, Light Microscopy, Expressing, MTT Assay

    Graphene oxide reduces the expression of stem cell markers and promotes the differentiation of GSCs. a Quantification of the mRNA levels of stem cell markers SOX2 and CD133 in GSCs with or without treatment with GO. b The intracellular expression of the differentiation marker GFAP after treatment with 50 μg/ml GO was examined using immunofluorescence staining. Scale bar = 100 μm. c The expression level of the stem cell marker CD133 in cells treated with different concentrations of GO was detected by immunofluorescence staining. Scale bar = 50 μm. d , e Representative immunoblots and relative quantification of OCT4, SOX2, TUJ1 and GFAP in GSCs after treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p
    Figure Legend Snippet: Graphene oxide reduces the expression of stem cell markers and promotes the differentiation of GSCs. a Quantification of the mRNA levels of stem cell markers SOX2 and CD133 in GSCs with or without treatment with GO. b The intracellular expression of the differentiation marker GFAP after treatment with 50 μg/ml GO was examined using immunofluorescence staining. Scale bar = 100 μm. c The expression level of the stem cell marker CD133 in cells treated with different concentrations of GO was detected by immunofluorescence staining. Scale bar = 50 μm. d , e Representative immunoblots and relative quantification of OCT4, SOX2, TUJ1 and GFAP in GSCs after treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p

    Techniques Used: Expressing, Marker, Immunofluorescence, Staining, Western Blot

    5) Product Images from "A rat model for studying neural stem cell transplantation"

    Article Title: A rat model for studying neural stem cell transplantation

    Journal: Acta Pharmacologica Sinica

    doi: 10.1038/aps.2009.151

    Immunohistochemistry of injected site of rat retinas. HE staining showed normal retinal structure (A). The nestin positive cells of BDNF-NSCs group (B, red arrow) existed between the retina and choroid at d 10 after transplantation. One month after transplantation, immunolabeling of retinal sections revealed that a few of transplanted cells expressed NSE (C: BDNF-NSCs, red arrows) and GFAP (D, BDNF-NSCs, red arrow) and lay in the outer nuclear layer (ONL) and exhibited neuronal-like morphologies. At 2 months after injected, immonuhischemical analysis demonstrated that most of the donor cells appeared to migrate to the deep retina. Within the ONL and outer plexiform layers (OPL) of the retina, we commonly observed bodies and processes of donor cells expressing NSE with extensive branching in the BDNF-NSCs group (E, long red arrows: bodies of cells; short red arrow: processes of cells). Whole mount analysis indicated that, 3 months after transplantation of donor cells into the subretinal space of normal rats, a few of NSE positive cells of BDNF-NSCs group had migrated into inner nuclear layer (INL) of the retina (F, red arrow). Graft of control-NSCs were still in ONL at 3 months (G, red arrows). A few of grafted cells lay in RPE (H, red arrow). BDNF, brain-derived neurotrophic factor; NSCs, neural stem cells; NSE, neurone specific enolase; GFAP, glial fibrillary acidic protein; ONL, outer nuclear layer; INL, inner nuclear layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium. Bars, 100 μm.
    Figure Legend Snippet: Immunohistochemistry of injected site of rat retinas. HE staining showed normal retinal structure (A). The nestin positive cells of BDNF-NSCs group (B, red arrow) existed between the retina and choroid at d 10 after transplantation. One month after transplantation, immunolabeling of retinal sections revealed that a few of transplanted cells expressed NSE (C: BDNF-NSCs, red arrows) and GFAP (D, BDNF-NSCs, red arrow) and lay in the outer nuclear layer (ONL) and exhibited neuronal-like morphologies. At 2 months after injected, immonuhischemical analysis demonstrated that most of the donor cells appeared to migrate to the deep retina. Within the ONL and outer plexiform layers (OPL) of the retina, we commonly observed bodies and processes of donor cells expressing NSE with extensive branching in the BDNF-NSCs group (E, long red arrows: bodies of cells; short red arrow: processes of cells). Whole mount analysis indicated that, 3 months after transplantation of donor cells into the subretinal space of normal rats, a few of NSE positive cells of BDNF-NSCs group had migrated into inner nuclear layer (INL) of the retina (F, red arrow). Graft of control-NSCs were still in ONL at 3 months (G, red arrows). A few of grafted cells lay in RPE (H, red arrow). BDNF, brain-derived neurotrophic factor; NSCs, neural stem cells; NSE, neurone specific enolase; GFAP, glial fibrillary acidic protein; ONL, outer nuclear layer; INL, inner nuclear layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium. Bars, 100 μm.

    Techniques Used: Immunohistochemistry, Injection, Staining, Transplantation Assay, Immunolabeling, Expressing, Derivative Assay

    (A) primary neural stem cells. A cell became to divide at d 2 after plating single cells in single wells of 96-well plates (B) and proliferated continually at d 6 (C), and neurosphere composed of several decades of cells were formed at day 10 (D). (E–F) Immunocytochemical staining of differentiated neural stem cells (NSCs). (E) nestin; (F) GFAP (glial fibrillary acidic protein); (G) NSE (neurone specific enolase). Bars: 100 μm.
    Figure Legend Snippet: (A) primary neural stem cells. A cell became to divide at d 2 after plating single cells in single wells of 96-well plates (B) and proliferated continually at d 6 (C), and neurosphere composed of several decades of cells were formed at day 10 (D). (E–F) Immunocytochemical staining of differentiated neural stem cells (NSCs). (E) nestin; (F) GFAP (glial fibrillary acidic protein); (G) NSE (neurone specific enolase). Bars: 100 μm.

    Techniques Used: Staining

    6) Product Images from "Oxygen-Glucose Deprivation Induced Glial Scar-Like Change in Astrocytes"

    Article Title: Oxygen-Glucose Deprivation Induced Glial Scar-Like Change in Astrocytes

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0037574

    Effect of cerebral ischemia on neurocan expression in the penumbra region in rats. Fluorescent double immunostaining of neurocan and GFAP at 7 d after tMCAO in rats were performed (GFAP: red; neurocan: green; B (d-f) was the enlarged image from the penumbra region indicated by arrow in A; B (a-c) showed the image of the same region in sham group). The negative control by doing the same immunohistochemistry procedure without incubating with anti-neurocan was shown in g-i. DAB histochemistry staining of neurocan at different reperfusion duration after tMCAO were performed and the image from the penumbra region or contralateral (contra) region are shown in C. (D) Western blot analysis of neurocan expression (major core bands are about 150, 190, and 270 kD), which was normalized by GAPDH (∼37 kD). A: scale bars = 1 mm; B, C: scale bars = 25 µm. Values are expressed as percentage or fold change of control values and are from 3 to 6 rats.
    Figure Legend Snippet: Effect of cerebral ischemia on neurocan expression in the penumbra region in rats. Fluorescent double immunostaining of neurocan and GFAP at 7 d after tMCAO in rats were performed (GFAP: red; neurocan: green; B (d-f) was the enlarged image from the penumbra region indicated by arrow in A; B (a-c) showed the image of the same region in sham group). The negative control by doing the same immunohistochemistry procedure without incubating with anti-neurocan was shown in g-i. DAB histochemistry staining of neurocan at different reperfusion duration after tMCAO were performed and the image from the penumbra region or contralateral (contra) region are shown in C. (D) Western blot analysis of neurocan expression (major core bands are about 150, 190, and 270 kD), which was normalized by GAPDH (∼37 kD). A: scale bars = 1 mm; B, C: scale bars = 25 µm. Values are expressed as percentage or fold change of control values and are from 3 to 6 rats.

    Techniques Used: Expressing, Double Immunostaining, Negative Control, Immunohistochemistry, Staining, Western Blot

    7) Product Images from "Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1"

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1

    Journal: bioRxiv

    doi: 10.1101/2020.05.20.106153

    EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.
    Figure Legend Snippet: EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.

    Techniques Used: Expressing, Immunohistochemistry, Staining, Mouse Assay, Western Blot

    A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.
    Figure Legend Snippet: A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.

    Techniques Used: Cell Culture, Staining, Immunohistochemistry, Expressing, Western Blot

    Related Articles

    Incubation:

    Article Title: Effects of Long-Term Endogenous Corticosteroid Exposure on Brain Volume and Glial Cells in the AdKO Mouse
    Article Snippet: .. Sections were then incubated with antibodies for MBP (MAB386, Merck Millipore; 1:1,000), GFAP (PA1239, Boster Bio, 1:200), or Iba1 (019-19741, Wako Chemical, 1:1,000) diluted in PBSTG, overnight at 4°C. ..

    Article Title: Let-7f promotes the differentiation of neural stem cells in rats
    Article Snippet: .. Then NSCs were fixed with 4% paraformaldehyde at room temperature (RT) and permeabilized with 0.1 Triton X-100, followed by blocking with 5% FBS and incubation with the following primary antibodies: rabbit anti-Nestin antibody (Abcam, Cambridge, UK; dilution 1:100), mouse anti-Tuj1 antibody (Beyotime Biotechnology; dilution 1:100), and rabbit anti-GFAP antibody (Boster Biological Technology; dilution 1:100). ..

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1
    Article Snippet: .. The blots were incubated overnight at 4°C with the primary antibody [rat anti-C3 (1:50; abam, UK), rabbit anti-GFAP (1:1000; Boster, China), rabbit anti-GLT-1 (1:1000; Thermo Fisher Scientific, USA), rabbit anti-GLAST (1:1000; abcam, UK), mouse anti-GS (1:1000; abcam, UK), mouse anti-S100A10 (1:1000; Thermo Fisher Scientific, USA). ..

    Article Title: Abnormal Glu/mGluR2/3/PI3K pathway in the hippocampal neurovascular unit leads to diabetes-related depression
    Article Snippet: .. Afterward, they were incubated in 0.25% Triton X-100, for 15 minutes, and blocked in 5% bovine serum albumin for 30 minutes, before incubation with different primary antibodies (neuron-specific enolase: 1:100, Cat# BA0535, Boster, Wuhan, China; glial fibrillary acidic protein: 1:200, Cat# BA0056, Boster; platelet endothelial cell adhesion molecule-1/CD31: 1:100, Cat# BA2966, Boster). ..

    Blocking Assay:

    Article Title: Let-7f promotes the differentiation of neural stem cells in rats
    Article Snippet: .. Then NSCs were fixed with 4% paraformaldehyde at room temperature (RT) and permeabilized with 0.1 Triton X-100, followed by blocking with 5% FBS and incubation with the following primary antibodies: rabbit anti-Nestin antibody (Abcam, Cambridge, UK; dilution 1:100), mouse anti-Tuj1 antibody (Beyotime Biotechnology; dilution 1:100), and rabbit anti-GFAP antibody (Boster Biological Technology; dilution 1:100). ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Boster Bio rabbit anti glial fibrillary acidic protein gfap
    Morphological and immunocytochemical characteristics of the hippocampal NVU. (A) Hippocampal neurons, astrocytes and <t>microvascular</t> endothelial cells under an inverted light microscope. (B) Neurons are positive for NSE (arrows), astrocytes express <t>GFAP</t> (arrows), and brain microvascular endothelial cells are positive for CD31 (arrows). Scale bars: 100 μm. NVU: Neurovascular unit; NSE: neuron-specific enolase; GFAP: glial fibrillary acidic protein.
    Rabbit Anti Glial Fibrillary Acidic Protein Gfap, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti glial fibrillary acidic protein gfap/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti glial fibrillary acidic protein gfap - by Bioz Stars, 2021-09
    94/100 stars
      Buy from Supplier

    95
    Boster Bio rabbit anti gfap
    EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of <t>C3</t> in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), <t>GFAP</t> (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.
    Rabbit Anti Gfap, supplied by Boster Bio, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti gfap/product/Boster Bio
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti gfap - by Bioz Stars, 2021-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    Morphological and immunocytochemical characteristics of the hippocampal NVU. (A) Hippocampal neurons, astrocytes and microvascular endothelial cells under an inverted light microscope. (B) Neurons are positive for NSE (arrows), astrocytes express GFAP (arrows), and brain microvascular endothelial cells are positive for CD31 (arrows). Scale bars: 100 μm. NVU: Neurovascular unit; NSE: neuron-specific enolase; GFAP: glial fibrillary acidic protein.

    Journal: Neural Regeneration Research

    Article Title: Structural and functional damage to the hippocampal neurovascular unit in diabetes-related depression

    doi: 10.4103/1673-5374.244794

    Figure Lengend Snippet: Morphological and immunocytochemical characteristics of the hippocampal NVU. (A) Hippocampal neurons, astrocytes and microvascular endothelial cells under an inverted light microscope. (B) Neurons are positive for NSE (arrows), astrocytes express GFAP (arrows), and brain microvascular endothelial cells are positive for CD31 (arrows). Scale bars: 100 μm. NVU: Neurovascular unit; NSE: neuron-specific enolase; GFAP: glial fibrillary acidic protein.

    Article Snippet: Astrocytes and brain microvascular endothelial cells were labeled with rabbit anti-glial fibrillary acidic protein (GFAP) (1:100; Boster) and rabbit anti-PECAM-1/CD31 (1:100; Boster) antibodies.

    Techniques: Light Microscopy

    Distribution of transplanted cells in the ischemic core of the brain on day 32 after transplantation in rats subjected to MCAO . Green labeling indicates BrdU-positive cells. DAPI (blue) labels nuclei. Immunofluorescent staining showing BrdU-positive transplanted cells (green) and NSE-positive cells (or GFAP-positive cells) (red). BrdU/NSE-positive double-labeled cells (or BrdU/GFAP-positive double-labeled cells) (yellow) (A,B) BMSC-N group; (C,D) BMSC group. The number of BrdU/GFAP-positive double-labeled cells or BrdU/NSE-positive double-labeled cells in the BMSC-N group was higher than that in the BMSC group. The BMSC-N group showed more BrdU/NSE-positive double-labeled cells than BrdU/GFAP-positive double-labeled cells. Conversely, the BMSC group had more BrdU/GFAP-positive double-labeled cells than BrdU/NSE-positive double-labeled cells. Significance levels are as shown in Table 3 . Scale bar = 100 μm.

    Journal: Frontiers in Neurology

    Article Title: In Vitro Differentiation of Bone Marrow Mesenchymal Stem Cells into Neuron-Like Cells by Cerebrospinal Fluid Improves Motor Function of Middle Cerebral Artery Occlusion Rats

    doi: 10.3389/fneur.2016.00183

    Figure Lengend Snippet: Distribution of transplanted cells in the ischemic core of the brain on day 32 after transplantation in rats subjected to MCAO . Green labeling indicates BrdU-positive cells. DAPI (blue) labels nuclei. Immunofluorescent staining showing BrdU-positive transplanted cells (green) and NSE-positive cells (or GFAP-positive cells) (red). BrdU/NSE-positive double-labeled cells (or BrdU/GFAP-positive double-labeled cells) (yellow) (A,B) BMSC-N group; (C,D) BMSC group. The number of BrdU/GFAP-positive double-labeled cells or BrdU/NSE-positive double-labeled cells in the BMSC-N group was higher than that in the BMSC group. The BMSC-N group showed more BrdU/NSE-positive double-labeled cells than BrdU/GFAP-positive double-labeled cells. Conversely, the BMSC group had more BrdU/GFAP-positive double-labeled cells than BrdU/NSE-positive double-labeled cells. Significance levels are as shown in Table 3 . Scale bar = 100 μm.

    Article Snippet: The slices were stained alternatively for neuronal specific enolase (NSE, neuronal marker) or rabbit anti-rats glial fibrillary acidic protein (GFAP, a astrocyte marker), mouse anti-BrdU antibody (1:100), rabbit anti-rats NSE antibody (1:200; Wuhan Boster Biological Technology, Ltd., China) or rabbit anti-rats GFAP antibody (1:200; Wuhan Boster Biological Technology, Ltd., China) at 37°C.

    Techniques: Transplantation Assay, Labeling, Staining

    Characteristics of hCSF-induced rat BMSC-differentiated neuron-like cells . (A,B) show post-induction by hCSF at day 1 and 4 (40×). Scale bar = 100 μm. (C) The protein levels were measured by a GELDOC instrument and normalized with respect to β-actin, which was chosen as an internal control. Each experiment was repeated at least three times. Variations in protein expression are given as arbitrary units. The expression of NES in cells induced by hCSF (0.43 ± 0.07) was significantly higher than that of P3-generation BMSCs (0.09 ± 0.03); meanwhile, GFAP also had small amount of expression (0.09 ± 0.02). However, P3-generation of BMSCs almost did not express GFAP (0 ± 0). (D–F) show Cells were positive for both NSE and GFAP, but expression levels for NSE were higher than GFAP. Western blot analysis of NSE and GFAP protein expression (200×). Scale bar = 100 μm.

    Journal: Frontiers in Neurology

    Article Title: In Vitro Differentiation of Bone Marrow Mesenchymal Stem Cells into Neuron-Like Cells by Cerebrospinal Fluid Improves Motor Function of Middle Cerebral Artery Occlusion Rats

    doi: 10.3389/fneur.2016.00183

    Figure Lengend Snippet: Characteristics of hCSF-induced rat BMSC-differentiated neuron-like cells . (A,B) show post-induction by hCSF at day 1 and 4 (40×). Scale bar = 100 μm. (C) The protein levels were measured by a GELDOC instrument and normalized with respect to β-actin, which was chosen as an internal control. Each experiment was repeated at least three times. Variations in protein expression are given as arbitrary units. The expression of NES in cells induced by hCSF (0.43 ± 0.07) was significantly higher than that of P3-generation BMSCs (0.09 ± 0.03); meanwhile, GFAP also had small amount of expression (0.09 ± 0.02). However, P3-generation of BMSCs almost did not express GFAP (0 ± 0). (D–F) show Cells were positive for both NSE and GFAP, but expression levels for NSE were higher than GFAP. Western blot analysis of NSE and GFAP protein expression (200×). Scale bar = 100 μm.

    Article Snippet: The slices were stained alternatively for neuronal specific enolase (NSE, neuronal marker) or rabbit anti-rats glial fibrillary acidic protein (GFAP, a astrocyte marker), mouse anti-BrdU antibody (1:100), rabbit anti-rats NSE antibody (1:200; Wuhan Boster Biological Technology, Ltd., China) or rabbit anti-rats GFAP antibody (1:200; Wuhan Boster Biological Technology, Ltd., China) at 37°C.

    Techniques: Expressing, Western Blot

    EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.

    Journal: bioRxiv

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1

    doi: 10.1101/2020.05.20.106153

    Figure Lengend Snippet: EA rescued METH-related neurotoxicity via normalizing the function of astrocyte. A. Expression of C3 in the dCA1 during METH withdrawal. (A1), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of SAL and METH group mice. White arrows indicate representative cells which were showed at a higher power view in the white box. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, numbers of GFAP-positive cells per mm 2 in SAL and METH groups. (A2), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of SAL and METH groups. (A3), Top panels: immunohistochemistry staining for C3 (green), GFAP (red) and DAPI (blue) in the hippocampus of M+SEA and M+EA group mice. Bottom panels: left, the proportion of C3 and GFAP double-label cells; middle, the proportion of reactive astrocytes; right, number of GFAP-positive cells per mm 2 . (A4), Western blots (top) and quantification (bottom) of C3 and GFAP protein levels in the dCA1 of M+SEA and M+EA group. B, GLT-1, GLAST and GS expression levels in the dCA1 during METH withdrawal. (B1), Immunohistochemistry staining (left, GLT-1/GLAST/GS-green; GFAP-red and DAPI-blue) and colocalized ratio (right) for GLT-1, GLAST and GS in the hippocampus of SAL and METH group mice. (B2), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of SAL and METH group. (B3), Immunohistochemistry staining (left) and colocalized ratio (right) for GLT-1, GLAST and GS of M+SEA and M+EA group. (B4), Western blots (top) and quantification (bottom) of GLT-1, GLAST and GS protein levels in the dCA1 of M+SEA and M+EA group. Data are Mean ± S.E.M.

    Article Snippet: The following primary antibodies were used in these experiments: rat anti-C3 (1:200; abcam, UK), mouse anti-S100A10 (1:200; Thermo Fisher Scientific, USA), rabbit anti-GFAP (1:300; Boster, China), rat anti-GFAP(1:500, Thermo Fisher Scientific, USA), rabbit anti-GLT-1 (1:300; Cell Signaling Technology, USA), rabbit anti-GLAST (1:300; Thermo Fisher Scientific, USA), mouse anti-GS (1:500; abcam, UK), rabbit anti-c-Fos (1:2000; Cell Signaling Technology, USA), rabbit anti-SYP1 (Synaptotagmin-1, 1;500; Signalway Antibody, USA), mouse anti-VGLUT-1 (1;500; 1:200; abcam, UK), rabbit anti-NeuN (1:100; MERCK, Germany).

    Techniques: Expressing, Immunohistochemistry, Staining, Mouse Assay, Western Blot

    A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.

    Journal: bioRxiv

    Article Title: Electro-acupuncture Alleviates METH Withdrawal-induced Spatial Memory Deficits by Restoring Astrocyte-drived Glutamate Uptake in dCA1

    doi: 10.1101/2020.05.20.106153

    Figure Lengend Snippet: A1-like astrocytes showed decreased capacity of Glu uptake. A, Glu clearance in primary cultured astrocytes. (A1), Representative micrographs (left) and quantification (right) for GFAP staining in primary astrocytes. (A2), Top panels: immunohistochemistry micrographs for C3 (green), GFAP (red) and DAPI (blue) of control and A1 group. Bottom panels: left, ratio of C3 positive astrocytes; right, mRNA expression levels of C3. (A3), Ratio of Glu clearance after 1h application of Glu (100μM) in the control and A1 group. B, GLT-1, GLAST and GS expression in the primary cultured astrocytes. (B1) , Immunohistochemistry micrographs (left, GLT-1/GLAST/GS-red; C3-green and DAPI-blue) and quantification (right) for GLT-1, GS and GLAST of control and A1 group. (B2), Western blots (top) and quantification (bottom) of GLT-1, GS and GLAST protein levels of control and A1 group. Data are Mean ± S.E.M.

    Article Snippet: The following primary antibodies were used in these experiments: rat anti-C3 (1:200; abcam, UK), mouse anti-S100A10 (1:200; Thermo Fisher Scientific, USA), rabbit anti-GFAP (1:300; Boster, China), rat anti-GFAP(1:500, Thermo Fisher Scientific, USA), rabbit anti-GLT-1 (1:300; Cell Signaling Technology, USA), rabbit anti-GLAST (1:300; Thermo Fisher Scientific, USA), mouse anti-GS (1:500; abcam, UK), rabbit anti-c-Fos (1:2000; Cell Signaling Technology, USA), rabbit anti-SYP1 (Synaptotagmin-1, 1;500; Signalway Antibody, USA), mouse anti-VGLUT-1 (1;500; 1:200; abcam, UK), rabbit anti-NeuN (1:100; MERCK, Germany).

    Techniques: Cell Culture, Staining, Immunohistochemistry, Expressing, Western Blot

    Graphene oxide inhibits the cell viability and promotes the differentiation of U251 GSCs. a U251 cells were cultured in a serum-free environment. Sphere morphology was photographed using light microscopy. Scale bar = 100 μm. b The expression of SOX2, CD133 and OCT4 in glioblastoma stem-like cells was increased during different periods. c Morphological appearance of U251 GSCs with or without treatment with GO for 2 days. The GSC spheres treated with GO showed adherent growth. Scale bar = 100 μm. d An MTT assay showed the cell viability of U251 GSCs with or without treatment with different dosages of GO for 2, 4, and 6 days. e Quantification of the mRNA levels of the stem cell markers SOX2 and differentiation markers (GFAP and TUJ1) in U251 GSCs with or without treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p

    Journal: Journal of Translational Medicine

    Article Title: Graphene oxide suppresses the growth and malignancy of glioblastoma stem cell-like spheroids via epigenetic mechanisms

    doi: 10.1186/s12967-020-02359-z

    Figure Lengend Snippet: Graphene oxide inhibits the cell viability and promotes the differentiation of U251 GSCs. a U251 cells were cultured in a serum-free environment. Sphere morphology was photographed using light microscopy. Scale bar = 100 μm. b The expression of SOX2, CD133 and OCT4 in glioblastoma stem-like cells was increased during different periods. c Morphological appearance of U251 GSCs with or without treatment with GO for 2 days. The GSC spheres treated with GO showed adherent growth. Scale bar = 100 μm. d An MTT assay showed the cell viability of U251 GSCs with or without treatment with different dosages of GO for 2, 4, and 6 days. e Quantification of the mRNA levels of the stem cell markers SOX2 and differentiation markers (GFAP and TUJ1) in U251 GSCs with or without treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p

    Article Snippet: We performed incubation with anti-CD133 (1:200; PB0168, Boster) and anti-GFAP (1:200; BA0056, Boster) antibodies overnight, which was followed by incubation with secondary antibody for 1 h. The nuclear DNA was labeled with DAPI.

    Techniques: Cell Culture, Light Microscopy, Expressing, MTT Assay

    Graphene oxide reduces the expression of stem cell markers and promotes the differentiation of GSCs. a Quantification of the mRNA levels of stem cell markers SOX2 and CD133 in GSCs with or without treatment with GO. b The intracellular expression of the differentiation marker GFAP after treatment with 50 μg/ml GO was examined using immunofluorescence staining. Scale bar = 100 μm. c The expression level of the stem cell marker CD133 in cells treated with different concentrations of GO was detected by immunofluorescence staining. Scale bar = 50 μm. d , e Representative immunoblots and relative quantification of OCT4, SOX2, TUJ1 and GFAP in GSCs after treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p

    Journal: Journal of Translational Medicine

    Article Title: Graphene oxide suppresses the growth and malignancy of glioblastoma stem cell-like spheroids via epigenetic mechanisms

    doi: 10.1186/s12967-020-02359-z

    Figure Lengend Snippet: Graphene oxide reduces the expression of stem cell markers and promotes the differentiation of GSCs. a Quantification of the mRNA levels of stem cell markers SOX2 and CD133 in GSCs with or without treatment with GO. b The intracellular expression of the differentiation marker GFAP after treatment with 50 μg/ml GO was examined using immunofluorescence staining. Scale bar = 100 μm. c The expression level of the stem cell marker CD133 in cells treated with different concentrations of GO was detected by immunofluorescence staining. Scale bar = 50 μm. d , e Representative immunoblots and relative quantification of OCT4, SOX2, TUJ1 and GFAP in GSCs after treatment with 0, 5, 12.5, 25 and 50 μg/ml GO respectively. * p

    Article Snippet: We performed incubation with anti-CD133 (1:200; PB0168, Boster) and anti-GFAP (1:200; BA0056, Boster) antibodies overnight, which was followed by incubation with secondary antibody for 1 h. The nuclear DNA was labeled with DAPI.

    Techniques: Expressing, Marker, Immunofluorescence, Staining, Western Blot